Comparison of the solubility and dissolution rate between gliclazide solid complex and its nanospheres

Drug Development and Industrial Pharmacy

Volumn 33, Issue 3, 2007, Pages 301-309

  Lo, Yung Kuang ^a   Chen, Chiu Ju ^a   Tsai, Tong Rong ^a   Cham, Thau Ming ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cyclodextrin; Gliclazide; Nanospheres; Neutralization; Solubility

Indexed keywords

BETA CYCLODEXTRIN; GLICLAZIDE; NANOSPHERE;

ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DOSAGE FORM COMPARISON; DRUG SOLUBILITY; EVAPORATION; INFRARED SPECTROSCOPY; INTERMETHOD COMPARISON; NANOTECHNOLOGY; PRECIPITATION;

BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; GLICLAZIDE; HYPOGLYCEMIC AGENTS; NANOTUBES; PARTICLE SIZE; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 34247476151     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040600920622     Document Type: Article

References (34)

1. Aggarwal, S., Singh, P. N., & Mishra, B. (2002). Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin- hydroxypropylmethylcellulose complexes. Pharmazie, 57, 191-193.
2. Ammar, H. O., Ghorab, M., El-Nahhas, S. A., Emara, L. H., & Makram, T. S. (1999). Inclusion complexation of furosemide in cyclodextrins. Pharmazie, 54, 142-144.
3. Andersen, F. A., & Bundgaard, H. (1984). Inclusion complexation of metronidazole benzoate with β-cyclodextrin and its depression of anhydrate-hydrate transition in aqueous suspensions. Int. J. Pharm., 19, 189-197.
4. Bekers, O., Uijtendaal, E. V., Beijnen, J. H., Bult, A., & Underberg, W. J. M. (1991). Cyclodextrins in pharmaceutical field. Drug Dev. Ind. Pharm., 17, 1503-1549.
5. Blanco, J., Vila-Jato, J. L., Otero, F., & Anguiano, S. (1991). Influence of method of preparation on inclusion complexes of naproxen with different cyclodextrins. Drug Dev. Ind. Pharm., 17, 943-945.
6. Bodmeier, R., & Chen, H. (1990). Indomethacin polymeric nanosuspensions prepared by microfluidization. J. Control. Release, 12, 223-233.
7. Chow, D., & Karara, A. (1986). Characterization, dissolution and bioavailability in rats of ibuprofen-b-cyclodextrin complex system. Int. J. Pharm., 28, 95-101.
8. Couvreur, P., Dubernet, C., & Puisieux, F. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur. J. Pharm. Biopharm., 41, 2-13.
9. Eerikäinen, H., & Kauppinen, E. I. (2003). Preparation of polymeric nanoparticles containing corticosteroid by a novel aerosol flow reactor method. Int. J. Pharm., 263, 69-83.
10. Irie, T., & Uekama, K. (1997). Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci., 86, 147-162.
11. Jansen, T., Xhonneux, B., Mesens, J., & Borgers, M. (1990). Beta-cyclodextrins as vehicles in eye-drop formulations: an evaluation of their effects on rabbit corneal epithelium. Lens Eye Toxic. Res., 7, 459-468.
12. Jung, S. W., Jeong, Y. I., & Kim, S.H. (2003) Characterization of hydrophobized pullulan with various hyfrophobicities. Int. J. Pharm., 254, 109-121.
13. Kahn, C. R., & Shechter, Y. (1990). Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In Goodman and Gilmann's The Pharmacological Basis of Therapeutics (8th Ed.); Gilmann, A. G., Rall, T. W., Nies, A. S., & Taylor, P. (Eds.), Pergamon Press: New York; 1485-1486
14. Khan, K. A. (1975). The concept of dissolution efficiency. J. Pharm. Pharmacol., 27, 48-49.
15. Krishnamoorthy, R., Wolka, A. M., Shao, Z., & Mitra, A. K. (1995). Cyclodextrins as mucosal absorption promotors. IV: Evaluation of nasal mucotoxicity. Eur. J. Pharm. Biopharm., 41, 296-301.
16. Leroux, J. C., Allémann, E., Doelker, E., & Gurny, R. (1995). New approach for the preparation of nanoparticles by an emulsification-diffusion method. Eur. J. Pharm. Biopharm., 41, 14-18.
17. Leroy-Lechat, F., Wouessidjewe, D., Andreux, J. P., Puisieux, F., & Duchêne, D. (1994). Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivatives. Int. J. Pharm., 101, 97-103.
18. Loftsson, T., & Brewster, M. E. (1996). Pharmaceutical applications of cyclodextrins. I. Drug solubilisation and stabilization. J. Pharm. Sci., 85, 1012-1025.
19. Mesens, J. L., Putteman, P., & Verheyen, P. (1991). Pharmalogical application of 2-hydroxypropal-β-cyclodextrin. In New Trends in Cyclodextrins and Derivatives; Duchêne, D. (Ed.), Editions de Santê: Paris, France; 369-407.
20. Moyano, J. R., Arias-Blanco, M. J., Gines, J. M., & Giordano, F. (1997a). Solid-state characterization and dissolution characteristics of gliclazide-β-cyclodextrin inclusion complexes. Int. J. Pharm., 148, 211-217.
21. Moyano, J. R., Arias-Blanco, M. J., Gines, J. M., Rabasco, A. M., Perez-Martinez, J.I., Mor, M., & Giordano, F. (1997b). Nuclear magnetic resonance investigations of the inclusion complexation of gliclazide with beta-cyclodextrin. J Pharm Sci., 86, 72-75.
22. Müller, R.H., Jacobs, C., & Kayser, O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what can we expect for the future. Adv. Drug Deliv. Rev., 47, 3-19.
23. Otagiri, M., Imai, T., Hirayama, F., Uekama, K. & Yamasaki, M. (1983). Inclusion complex formations of the anti-inflammatory drug flurbiprofen with cyclodextrins in aqueous solution and in solid state. Acta Pharm. Suec., 20, 11-20.
24. Özkan, Y., Atay, T., Dikmen, N., Isimer, A., & Aboul-Enein, H. Y. (2000). Improvement of water solubility and in vitro dissolution rate of gliclazide by complexation with beta-cyclodextrin. Pharm. Acta Helv., 74, 365-370.
25. Pignatello, R., Ferro, M., & Puglisi, G. (2002). Preparation of solid dispersions of nonsteroidal anti-inflammatory drugs with acrylic polymers and studies on mechanisms of drug-polymer interactions. AAPS Pharm. Sci. Tech., 3, E10.
26. Pitha, J., Milecki, J., Fales, H., Pannell, L., & Uekama, K. (1986). Hydroxypropyl-β- cyclodextrin: preparation and characterization; effects on solubility of drugs. Int. J. Pharm., 29, 73-82.
27. Pitha, J., & Pitha, J. (1985). Amorphous water-soluble derivatives of cyclodextrins: nontoxic dissolution enhancing excipients. J. Pharm. Sci., 74, 987-990.
28. Redenti, E., Peveri, T., Zanol, M., Ventura, P., Gnappi, G., & Montenero, A. (1996). A study on the differentiation between amorphous piroxicam: β-cyclodextrin complex and a mixture of the two amorphous components. Int. J. Pharm., 129, 289-294.
29. Saenger, W. (1980). Cyclodextrin inclusion compounds in research and laboratory. Angew. Chem. Int. Ed. Engl., 19, 344-362.
30. Szejtli, J. (1998). Introduction and general overview of cyclodextrin chemistry. Chem. Rev., 98, 1743-1753.
31. Tessier, D., Dawson, K., Tetrault, J. P., Bravo, G., & Meneilly, G. S. (1994). Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet. Med., 11, 974-980.
32. Uekama, K., Hirayama, F., & Irie, T. (1991). Pharmaceutical uses of cyclodextrinderivatives. In High Performance Biomaterials, A Comprehensive Guide to Medical and Pharmaceutical Applications; Szycher, M. (Ed.), Technomic: Lancaster; 789-806.
33. Uekama, K., Masaki, K., Arimori, K., Irie, T., & Hirayama, F. (1987). Effects of beta- and dimethyl beta-cyclodextrins on release and percutaneous absorption behaviors of prednisolone from some ointment bases. Yakugaku Zasshi, 107, 449-456
34. Winters, C. S., York, P., & Timmins, P. (1997). Solid state examination of a gliclazide: beta-cyclodextrin complex. Eur. J. Pharm. Sci., 5, 209-214.